Scienture Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Scienture Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.83M | Mar 22, 2019 |
| FY2018 | Dec 31, 2017 | $2.93M | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | $2.48M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $2.91M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $1.50M | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | $955.9K | Mar 23, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $431.6K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $136.6K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.36M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $10.25M | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | $9.89M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $17.12M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $7.44M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $3.83M | Mar 30, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $331.5K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $49.0K | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $5.52M | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | $4.75M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.71M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $4.87M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $3.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.93M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.48M | Mar 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.51M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.07M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($17.84M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($3.47M) | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | ($5.32M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($2.54M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($284.4K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $9.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $289.0K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($2.76M) | Mar 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.59M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.70M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.40M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($2.92M) | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | ($5.29M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($2.51M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $125.2K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($87.6K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $395.1K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($1.01M) | Mar 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.96M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.24M | Mar 30, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.38M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.27M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($2.23M) | Mar 26, 2025 |
| FY2022 | Dec 31, 2022 | ($1.53M) | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | ($2.57M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($2.21M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $141.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $273.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $171.7K | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | ($503.5K) | Mar 30, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $12.0K | Mar 30, 2026 |
| FY2022 | Dec 31, 2021 | $22.6K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $37.5K | Mar 28, 2022 |
| FY2014 | Dec 31, 2013 | $11.0K | Mar 23, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $104.85M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $12.53M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $3.71M | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | $5.77M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $9.79M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $5.57M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.23M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $617.5K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $337.1K | Mar 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.06M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $25.78M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $11.99M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $3.37M | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.00M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.11M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.43M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.38M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $929.4K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $1.49M | Mar 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.12M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $79.07M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $542.4K | Mar 30, 2026 |
| FY2023 | Dec 31, 2022 | $763.1K | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.77M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $8.68M | Mar 28, 2022 |
| FY2021 | Dec 31, 2019 | $4.14M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $844.7K | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($311.9K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($1.15M) | Mar 22, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $21.37M | Mar 30, 2026 |
| FY2022 | Dec 31, 2022 | $0 | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 27, 2023 |
| FY2020 | Dec 31, 2019 | $726.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $726.0K | Mar 30, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($80.55M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($39.04M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($33.25M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($19.72M) | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | ($16.25M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($10.93M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($8.40M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($8.11M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($8.12M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($8.41M) | Mar 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.66M | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | $151.9K | Apr 22, 2024 |
| FY2023 | Dec 31, 2022 | $1.09M | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | $3.12M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.92M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.87M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $869.6K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $183.9K | Mar 2, 2018 |
| FY2017 | Dec 31, 2016 | $14.7K | Mar 2, 2018 |
| FY2017 | Dec 31, 2015 | $78.7K | Mar 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $2.90M | Mar 30, 2026 |
| FY2019 | Dec 31, 2019 | $225.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $522.1K | Mar 22, 2019 |
| FY2017 | Dec 31, 2017 | $666.5K | Mar 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 2, 2018 |
| FY2015 | Dec 31, 2015 | 0 | Mar 28, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (23) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 2, 2018 |
| FY2015 | Dec 31, 2015 | 0 | Mar 28, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 40.63M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 8.75M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 905,008 | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 626,247 | Apr 22, 2024 |
| FY2022 | Dec 31, 2021 | 8.17M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 8.09M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 6.54M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 5.55M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 31.99M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 31.66M | Mar 2, 2018 |